Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells

Normal Hematopoetik ve Multipl Myelom İlişkili Progenitor Hücrelerde Lokal Renin-Anjiotensin Sistemi

Burak Uz1, Suzin Çatal Tatonyan2, Müge Sayitoğlu2, Yücel Erbilgin2, Özden Hatranaz2, Salih Aksu1, Yahya Büyükaşık1, Nilgin Sayinalp1, Hakan Göker1, Osman İ. Özebe1, Uğur Özbek2, İbrahim C. Haznedaroğlu1

1Hacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey
2İstanbul University, Institute for Experimental Medicine Research, Department of Genetics, Istanbul, Turkey

Abstract:

Objective: The prominent functions of the local renin-angiotensin system (RAS) in primitive hematopoiesis further support the hypothesis that local autocrine bone marrow RAS could also be active in neoplastic hematopoiesis. The aim of this study is to examine critical RAS elements in normal CD34+ hematopoietic stem cells and multiple myeloma (MM)-related progenitor cells.

Materials and Methods: The study group comprised the total bone marrow cells (CBM) of 10 hematologically normal people, the CD34+ stem cell samples (CD34+CBM) of 9 healthy donors for allogeneic peripheral stem cell transplantation, and the CD34+ stem cell samples (CD34+MM) of 9 MM patients undergoing autologous peripheral stem cell transplantation. We searched for the gene expression of the major RAS components in healthy hematopoietic cells and myeloma cells by quantitative real-time polymerase chain reaction analysis.

Results: RENIN, angiotensinogen (ANGTS), and angiotensin converting enzyme-I (ACE I) mRNA expression levels of CBM were significantly higher than those in myeloma patients (p=0.03, p=0.002, and p=0.0008, respectively). Moreover, RENIN and ANGTS mRNA expression levels were significantly higher in CD34+ stem cell samples of healthy allogeneic donors compared to those in myeloma patients (p=0.001 and p=0.01). However, ACE I expression levels were similar in CD34+CBM and CD34+MM hematopoietic cells (p=0.89).

Conclusion: Although found to be lower than in the CBM and CD34+CBM hematopoietic cells, the local RAS components were also expressed in CD34+MM hematopoietic cells. This point should be kept in mind while focusing on the immunobiology of MM and the processing of autologous cells during the formation of transplantation treatment protocols.

Key Words: Renin-angiotensin system, Multiple myeloma, Progenitor cell, CD34+

Özet:

Amaç: Lokal renin-anjiotensin sisteminin (RAS) primitif hematopoezde önemli fonksiyonlara sahip olması, lokal otokrin kemik iliğin (Kİ) RAS’ının da neoplastik hematopoezde aktif olabileceğini hipotezini desteklemektedir. Bu çalışmamın amacı normal CD34+ hematopoetik kök hücreler ve multipl miyelom (MM) ilişkili progenitor hücrelerde kritik RAS elemanlarını araştırmaktır.

Address for Correspondence: Burak Uz, M.D., Hacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey
Phone: +90 312 305 15 43 E-mail: buraku78@gmail.com
Received/Geliş tarihi : January 11, 2013
Accepted/Kabul tarihi : April 17, 2013
Introduction

The local hematopoietic renin-angiotensin system (RAS) affects the essential steps of hematopoiesis in the bone marrow (BM) microenvironment [1,2,3,4]. Myelopoiesis, erythropoiesis, thrombopoiesis, and other cellular lineages are influenced by the actions of the local BM RAS [3]. Besides those cellular effects, the local RAS [4,5] is also active in the BM stromal niche for the crucial governing of hematopoietic functions [6,7]. The local BM RAS affects hematopoiesis via both altering the internal signals of transcription factors regulating gene expressions and mediating the external signals from the growth factors secreted from the BM microenvironmental hematopoietic and stromal cells [8,9,10,11].

The RAS affects numerous biological events that are important for the formation and function of blood cells. Apoptosis, cellular proliferation, intracellular signaling, mobilization, angiogenesis, fibrosis within the cytokine network, and many other essential pathological events are affected by the critical RAS molecules [3,4,5,12,13]. Malignant blood cells, including multiple myeloma (MM) cells, are derived from the clonal neoplastic stem cells within a complex series of pathological proliferative steps. The local BM RAS could affect neoplastic tumoral blood cell production [14,15,16,17,18,19,20,21,22]. The local RAS is effective even in embryonic hematopoiesis [23,24,25,26]. The prominent functions of the local RAS in primitive hematopoiesis further support the hypothesis that the local autocrine BM RAS could also be active in neoplastic hematopoiesis [3].

The aim of this study is to examine critical RAS elements in normal CD34+ hematopoietic stem cells and MM-related progenitor cells. For this purpose, CD34+ hematopoietic cells obtained from healthy peripheral allogeneic hematopoietic stem cell transplantation donors and from MM patients undergoing peripheral autologous stem cell transplantation were analyzed via quantitative real-time polymerase chain reaction analysis (qRT-PCR). Normal BM cells obtained from hematologically normal people were also studied to detect the impact of precursor cell compartments on RAS expressions. Elucidation of the status of the local RAS molecules in early and neoplastic hematopoiesis represents a clinically relevant basic research area for better understanding of the biology of the diseases [4,5].

Materials and Methods

Study Population

The study group comprised the total bone marrow cells (CBM) of 10 normal people, the CD34+ stem cell samples (CD34+CBM) of 9 healthy donors for allogeneic peripheral stem cell transplantation, and the CD34+ stem cell samples (CD34+MM) of 9 MM patients undergoing autologous peripheral stem cell transplantation. The diagnoses of MM were reached based on the criteria of the International Myeloma Working Group [27]. At the time of the sample collection, all of the patients were in good health and well hydrated. Written informed consent was obtained from all participants and the study protocol was approved by the local ethics committee of Hacettepe University.

Isolation of RNA and Synthesis of cDNA

Stem cell samples were collected in 2 mL ethylenediaminetetraacetic acid tubes. Total RNA was isolated according to the manufacturer's instructions (QIAGEN, Germany). RNA quality was measured by spectrophotometer (ND-1000, NanoDrop Technologies, Inc., USA), and 1 µg of total RNA was used. Random primers (20 µM, Roche Diagnostics, Germany), 10 mM dNTP set (Fermentas UAB, Lithuania), RiboLock RNase Inhibitor (20 U/µL, Fermentas) and Moloney murine leukemia virus reverse transcriptase (200 U/µL, Fermentas) were used for cDNA synthesis. cDNA samples were stored at -20 °C.
Quantitative Real-Time Polymerase Chain Reaction Analysis

We searched for the gene expression of the major RAS components including RENIN, angiotensinogen (ANGTS), angiotensin converting enzyme-I (ACE I), ACE II, angiotensin receptor-I (AGTR I), and AGTR II in healthy hematopoietic cells and myeloma cells by qRT-PCR. Previously designed primer-probes were used [28]. mRNA levels were normalized to CYPA and B-ACTIN genes.

The qRT-PCR analyses were performed using a LightCycler 480 instrument (Roche Diagnostics). Real-time amplification was performed with a final reaction mixture of 20 µL containing 5 µM of each primer, 0.5 µM of each probe, LightCycler 480 Probe Master Mix, and 100 ng/µL of cDNA. Each sample was studied in duplicate and all runs were repeated twice. The PCR protocol was as follows: initial denaturation at 95 °C for 7 min, and amplification segment at 5 s at 95 °C, 10 s at 60 °C, and 10 s at 72 °C for 45 cycles. The 2-Ct method was used to calculate relative expression levels determined from the qRT-PCR experiments [29] and results were given as percentages.

Statistical

SPSS 15.0 (SPSS Inc., USA) was used for all statistical analyses. The results were given as mean ± standard error for the data with normal distribution, as median (min-max) for the data without a normal distribution, and as ratio for the nominal data. Data distribution was tested with the Kolmogorov-Smirnov test. Homogeneities of variances were evaluated with Levene’s test. Nonparametric tests were used since the sample sizes of the groups were small. Differences between 2 groups were assessed by the Mann-Whitney U test. A p-value of ≤0.05 was considered statistically significant.

Results

Patient Characteristics

Five female and 4 male myeloma patients with a median age of 52 (40-62) years were recruited. Based on the International Staging System, 4 had stage I, 2 had stage II, and 2 had stage III disease. One patient could not be evaluated due to the lack of initial data.

Relative mRNA Expressions of the RAS Components in the Studied Cellular Samples

RENIN, ANGTS, and ACE I mRNA expression levels of CBM were significantly higher than those in myeloma patients (p=0.03, p=0.002, and p=0.0008, respectively; Figures 1, 2, 3). Moreover, RENIN and ANGTS mRNA expression levels were significantly higher in CD34+ stem cell samples of healthy allogeneic donors compared to those in myeloma patients (p=0.001 and p=0.01; Figures 1 and 2). However, ACE I expression levels were similar in the CD34+CBM and CD34+MM groups (p=0.89; Figure 3). Relative expression levels of RENIN, ANGTS, and ACE I genes in CD34+MM cells compared to CD34+CBM cells are given in Table 1. Other RAS pathway members’ (ACE II, AGTR I, and AGTR II) expressions were also examined and were not found to be at detectable levels, and no significant differences were determined between any groups.

Discussion

In the present study, RENIN and ANGTS mRNA expressions were significantly higher in CD34+ hematopoietic stem cells of healthy allogeneic donors in comparison to myeloma-related progenitor cells. Likewise, RENIN, ANGTS, and ACE I mRNA expression levels of CBM were significantly higher than those in the myeloma patients. However, ACE I expression levels were similar in CD34+CBM and CD34+MM hematopoietic cells. These findings support our original hypothesis that there is a biologically active local RAS in the hematopoietic system in normal and pathological states [1,2].

Strawn et al. previously verified in rats that all of the main RAS components, including renin, ANGTS, ACE,
and AGTR I, are detectable in the normal rat BM cellular compartment and rat microenvironmental stroma at the molecular and protein levels [6]. In the present study, we have found RENIN, ANGTS, and ACE I mRNA expressions in CD34+ stem cell samples of normal human subjects. ACE/CD143 was implicated in enhancing the recruitment of primitive stem cells into the S-phase by degrading AcSDKP [9,30,31,32,33]. ACE, converting Ang-I into Ang-II, is an important peptide for almost all aspects of hematopoiesis [23,31,34,35,36]. Myelopoietic effects of ACE and Ang-II are evident at the hematopoietic stem cell level, extending to the committed myeloid and erythroid lineages [35]. Hence, the local hematopoietic RAS seems to be effective in all species for cellular development. Hematopoiesis [37], myelopoiesis [35], erythropoiesis [38], thrombopoiesis [9], and other cellular lineages [37,39,40,41] are regulated by the actions of the peptides of the local BM RAS. The local BM RAS mediates those complicated networks of BM hematopoiesis in an autocrine/paracrine/intracrine fashion. The growth, production, proliferation and differentiation of the blood cells are affected by the hematopoietic RAS [1,4,5].

The local RAS is also expressed in the cellular compartment of the immunohematological system. The RAS is active in the production and function of distinct blood cell lineages such as dendritic cells, mast cells, T lymphocytes, monocytes, macrophages, and antigen-presenting cells [4,5]. For instance, ACE degrades substance P present in the BM microenvironment, lymphoblasts, and lymphocytes by cleaving a C-terminal dipeptide or tripeptide [41]. Stegbauer et al. reported the up-regulation of renin, ACE, and AGTR I in the immune system, including antigen-presenting cells in myelin-oligodendrocyte glycoprotein-induced experimental autoimmune diseases [42]. In this study, CD34+MM hematopoietic cells also locally expressed RENIN, ANGTS, and ACE I mRNA, indicating the activity of RAS in myeloma-related progenitor cells. ACE activity was also linked to MM [43,44]. BM AGTR I expression levels of myeloma patients showed a positive correlation with their BM infiltration pattern and tumor load, indicated by serum β2 microglobulin levels [44]. Our results about myeloma-related progenitors in this study provide an additional clue for the local RAS effects in the pathobiology of MM.

Recent studies [23,24,25,26] focused on the status of ACE within the context of the local RAS, the earliest human embryonic hematopoietic stem cells [45], and the developmental sequence underlying the ontogeny of human blood cells. The local RAS regulates the genesis and function of the hematopoietic system starting from embryonic life [25]. Human embryonic stem cell-derived ACE+CD45-CD34+-/- cells are the common yolk sac-like progenitors for not only the endothelium, but also for both primitive and definitive human lymphohematopoietic stem cells [26]. Human angiohematopoiesis initiates from an ACE-hemangioblastic progenitor of primitive and definitive hematopoiesis under the functional activities of the local RAS [26]. Sinka et al. [24] searched for the presence of ACE in the earliest pre-aorta-gonad-mesonephros stages of human intraembryonic angiohematopoiesis. At the earliest stages of human development, hematopoietic potential in the splanchnopleura is restricted to emerging CD34-ACE+ precursors. ACE expression has functions...
in the maintenance of embryonic hematopoiesis [24].
The results of the present study show that the main RAS
components are present in early hematopoietic stem
cells and progenitors as well as BM stem, progenitor,
and precursor cells. Therefore, manipulation of RAS
action could be an important strategy for the expansion
of multipotent hematopoietic progenitors during
hematopoietic stem cell–related management procedures
[46].

The development of MM depends upon deregulation in
a complex series of neoplastic pathobiological events. The
local tissue RAS influences tumor growth and metastases
in an autocrine and paracrine fashion, via the modulation
of numerous carcinogenic events such as angiogenesis,
apoptosis, cellular proliferation, immune responses, cell
signaling, and extracellular matrix formation. Potential
manipulation of the local RAS with many enzymes, peptides,
and feedback mechanisms can even represent a therapeutic
target for the clinical management of cancer [34,47,48].
Our findings about the CD34+MM hematopoietic cells,
which locally express critical RAS components in the
myeloma-related progenitor cells, could be a starting point
for future studies functions on the immunobiology of MM
and processing of autologous cells during the formation
of transplantation treatment protocols.

Future experimental and clinical studies are needed to elucidate the puzzling functions of local tissue RASs,
including the local BM RAS. These efforts should focus on dissecting local RAS interactions with the complicated
pathobiological characteristics of neoplastic disorders and
on manipulating autocrine-paracrine-intracrine systems for
better clinical management of patients with hematological
neoplastic disorders.

Conflict of Interest Statement
The authors of this paper have no conflicts of interest,
including specific financial interests, relationships, and/or
affiliations relevant to the subject matter or materials
included.

References
1. Haznedaroğlu IC, Tuncer S, Gürsoy M. A local renin-
angiotensin system in the bone marrow. Med Hypotheses
1996;46:507-510.
2. Haznedaroğlu IC. A local renin-angiotensin system in the
bone marrow still awaits its Christopher Columbus. Exp
Hematol 1998;26:279.
3. Haznedaroğlu IC, Beyazit Y. Local bone marrow renin-
angiotensin system in primitive, definitive and neoplastic
hematopoiesis. Clin Sci (Lond) 2013;124:307-323.
4. Haznedaroğlu IC, Beyazit Y. Pathobiological aspects of
the local bone marrow renin-angiotensin system: a review. J
Renin Angiotensin Aldosterone Syst 2010;11:205-213.
5. Haznedaroğlu IC, Öztürk MA. Towards the understanding
of the local hematopoietic bone marrow renin-angiotensin
system. Int J Biochem Cell Biol 2003;35:867-880.
6. Strawn WB, Richmond RS, Tallant EA, Gallagher PE,
Ferrario CM. Renin-angiotensin system expression in
rat bone marrow haematopoietic and stromal cells. Br J
Hematol 2004;126:120-126.
7. Huang YL, Kuang J, Hu YZ, Song YB, Qiu RF, Mai WY.
Bone marrow stromal cell transplantation combined with
angiotensin-converting enzyme inhibitor treatment in rat
with acute myocardial infarction and the role of insulin-like
growth factor-1. Cytotherapy 2012;14:563-569.
8. Haznedaroğlu IC, Arici M, Büyükaşık Y. A unifying
hypothesis for the renin-angiotensin system and
hematopoiesis: sticking the pieces together with the JAK-
STAT pathway. Med Hypotheses 2000;54:80-83.
9. Kwiatkowski BA, Richard RE. Angiotensin II receptor-
associated protein (AGTRAP) synergizes with Mpl signaling
to promote survival and to increase proliferation rate of
hematopoietic cells. ASH Annual Meeting Abstracts
2009;114:3606.
10. Öztürk MA, Güven GS, Haznedaroğlu IC. How hematopoietic
stem cells know and act in cardiac microenvironment
for stem cell plasticity? Impact of local renin-angiotensin
systems. Med Hypotheses 2004;63:866-874.
11. Vrsalovic MM, Pejsa V, Veic TS, Kolonic SO, Ajdukovic R,
Haris V, Jaksic O, Kusec R. Bone marrow renin-angiotensin
system expression in polycythemia vera and essential
thrombocytopenia depends on JAK2 mutational status.
Cancer Biol Ther 2007;6:1434-1436.
12. Durik M, Seva Pessoa B, Roks AJ. The renin-angiotensin
system, bone marrow and progenitor cells. Clin Sci (Lond)
2012;123:205-223.
13. Heringer-Walther S, Eckert K, Schumacher SM, Uharek L,
Wulf-Goldenberg A, Gembardt F, Fichtner I, Schultheiss
HP, Rodgers K, Walther T. Angiotensin-(1-7) stimulates
to hematopoietic progenitor cells in vitro and in vivo.
Haematologica 2009;94:857-860.
14. Abali H, Haznedaroğlu IC, Goker H, Çelik I, Özali D, Koray
Z, Çağlar M. Circulating and local bone marrow renin-
angiotensin system in leukemic hematopoiesis: preliminary
evidences. Hematology 2002;7:75-82.
15. Aksu S, Beyazit Y, Haznedaroğlu IC, Canpınar H, Kekilli
M, Uner A, Sayınalp N, Büyükaşık Y, Goker H, Ozcbe OI.
Over-expression of angiotensin-converting enzyme (CD
143) on leukemia blasts as a clue for the activated local bone
marrow RAS in AML. Leuk Lymphoma 2006;47:891-896.
16. Aksu S, Beyazit Y, Haznedaroğlu IC, Kekilli M, Canpınar
H, Misriğlioğlu M, Uner A, Tuncer S, Sayınalp N, Büyükaşık
Y, Goker H, Ozcbe OI. Enhanced expression of the local
hematopoietic bone marrow renin-angiotensin system in
polycythemia rubra vera. J Int Med Res 2005;33:661-667.
17. Beyazit Y, Aksu S, Haznedaroğlu IC, Kekilli M, Misirlioglu M, Tuncer S, Karakaya J, Koca E, Buyukasik Y, Sayinalp N, Goker H. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc 2007;99:57-63.

18. Casares MTG, De la Iglesias S, Perera M, Lemes A, Campo C, Gonzalez San Miguel JD, Bosch JM, Suarez A, Guerra L, Rodriguez-Peréz JC, Molero T. Renin expression in hematological malignancies and its role in the regulation of hematopoiesis. Leukemia 2002;43:2377-2381.

19. Inigo SDL, Casares MTG, Jorge CEL, Leiza SM, Santana GS, Bravo de Laguna SJ, San Miguel JD, Caballero A, Alvarez Mdel M, Castellano AL, Henriquez HL, Labarta TM. Relevance of renin expression by real-time PCR in acute myeloid leukemia. Leuk Lymphoma 2006;47:409-416.

20. Khodunova EE, Parovichnikova EN, Gaîtseva IV, Kulikov SM, Isaev VG, Savchenko VG. Dynamic study of Bcl-2, Bax, p53, and ACE expression in CD34+ cells of peripheral blood and bone marrow in acute leukemia patients in the course of induction chemotherapy. Ter Arkh 2011;83:32-37.

21. Wulf GG, Jahns-Streubel G, Nobiling R, Strutz F, Hemmerlein B, Hiddemann W, Wörmann B. Renin in acute myeloid leukemia. Leuk Lymphoma 1998;10:335-337.

22. Koca E, Haznedaroğlu IC, Akar K, Beyazit Y, Aksu S, Misirlioglu M, Tuncer S, Sayinalp N, Ozcebe OI, Uner A. Renin-angiotensin system expression in the K562 human erythroleukaemic cell line. J Renin Angiotensin Aldosterone Syst 2007;8:145-147.

23. Jokubaitis VJ, Sinka L, Driessen R, Whitty G, Haylock DN, Bertoncello I, Smith I, Péault B, Tavian M, Simmons PJ. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 2008;111:4055-4063.

24. Sinka L, Biasch K, Khazaal I, Peault B, Tavian M. Angiotensin-converting enzyme (CD143) specifies emerging lymphopoietic progenitors from human pluripotent stem cells. Blood 2012;119:3712-3723.

25. Tavian M, Biasch K, Sinka L, Vallet J, Peault B. Embryonic origin of human hematopoiesis. Int J Dev Biol 2010;54:1061-1065.

26. Zambidis ET, Soon Park T, Yu W, Tam A, Levine M, Yuan X, Pryzhkova M, Peault B. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008;112:3601-3614.

27. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.

28. Uz B, Catal Tatoyan S, Sayioglu M, Erbilgin Y, Hatirmaz Ng O, Buyukasik Y, Sayinalp N, Aksu S, Goker H, Ozcebe OI, Ozbek U, Haznedaroğlu IC. Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders. J Renin Angiotensin Aldosterone Syst 2013;14:308-314.

29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) Method. Methods 2001;25:402-408.

30. Comte L, Lorget V, Bignon J, Volkov L, Dupuis F, Wdzieczak-Bakala J, Praloran V. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide. Eur J Clin Invest 1998;28:856-863.

31. Comte L, Lorget V, Volkov L, Allegraud A, Algiedier JC, Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest 1997;27:788-790.

32. Li J, Volkov L, Comte L, Herve P, Praloran V, Charbord P. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp Hematol 1997;25:140-146.

33. Oliveira CR, Paredes-Gamero EJ, Barbosa CM, Nascimento FD, Batista EC, Reis FC, Martins AH, Ferreira AT, Carmona AK, Pesquero JB, Tersariol IL, Aratújo RC, Bincoletto C. Myelopoiesis modulation by ACE hyperfunction in kinin B1 receptor knockout mice: relationship with AcSDKP levels. Chem Biol Interact 2010;184:388-395.

34. Abahi H, Gillüü IH, Engin H, Haznedaroğlu IC, Erman M, Tekuzman G. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses 2002;59:344-348.

35. Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, Billet S, Bernstein KE, Shen XZ. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J 1997;25:1145-1155.

36. Marusic-Vrsalovic M, Dominis M, Jaksic B, Kusic R. Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol 2003;123:539-541.

37. Hubert C, Savary K, Gasc JM, Corvol P. The hematopoietic system: a new niche for the renin-angiotensin system. Nat Clin Pract Cardiovasc Med 2006;3:80-85.

38. Kato H, Ishida J, Imagawa S, Saito T, Suzuki N, Matsuoka T, Sugaya T, Tanimoto K, Yokoo T, Ohneda O, Sugiyama F, Yagami K, Fujita T, Yamamoto M, Nangaku M, Fukamizu A. Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. FASEB J 2005;19:2023-2025.
39. Hara M, Ono K, Wada H, Sasayama S, Matsumori A. Preformed angiotensin II is present in human mast cells. Cardiovasc Drugs Ther 2004;18:415-420.

40. Park TS, Zambidis ET. A role for the renin-angiotensin system in hematopoesis. Haematologica 2009;94:745-747.

41. Shen XZ, Bernstein KE. The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle 2011;10:1363-1369.

42. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 2009;106:14942-14947.

43. Albayrak M, Celebi H, Albayrak A, Sayilir A, Yesil Y, Balcik OS, Yokus O, Celik T. Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin-angiotensin system activation in multiple myeloma. J Renin Angiotensin Aldosterone Syst 2012;13:259-264.

44. Saka B, Dogan O, Tascioglu C, Besisik SK, Karan MA, Sayitoglu S, Erten N, Gene S. Bone marrow renin-angiotensin system in multiple myeloma. Clin Lymphoma Myeloma Leuk 2009;9:S10.

45. Tavian M, Peault B. The changing cellular environments of hematopoesis in human development in utero. Exp Hematol 2005;33:1062-1069.

46. Peters A, Burridge PW, Pryzhkova MV, Levine MA, Park TS, Roxbury C, Yuan X, Peault B, Zambidis ET. Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells. Int J Dev Biol 2010;54:965-990.

47. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29:1675-1684.

48. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010;10:745-759.